Treść książki
Przejdź do opcji czytnikaPrzejdź do nawigacjiPrzejdź do informacjiPrzejdź do stopki
ZESPÓŁMETAbOliCZNY
35
39.KolovouG.D.,AnagnostopoulouK.K.,DaskalopoulouS.S.etal.:Clinicalrelevanceofpostprandiallipaemia.Curr.Med.
Chem.2005;12:1931-45.
40.AvramogluR.K.,BascianoH.,AdeliK.:Lipidandlipoproteindysregulationininsulinresistantstates.Clin.Chim.Acta
2006;368:1-19.
41.CahováM.,VavrínkováH.,KazdováL.:Glucose-fattyacidinteractioninskeletalmuscleandadiposetissueininsulin
resistance.Physiol.Res.2007;56:1-15.
42.StorzP.,DöpplerH.,WernigA.etal.:Cross-talkmechanismsinthedevelopmentofinsulinresistanceofskeletalmuscle
cellspalmitateratherthantumournecrosisfactorinhibitsinsulin-dependentproteinkinaseB(PKB)/Aktstimulation
andglucoseuptake.Eur.J.Biochem.1999;266:17-25.
43.TsengC.H.,TsengC.P.,ChongC.K.etal.:Independentassociationbetweentriglyceridesandcoronaryarterydiseasein
Taiwanesetype2diabeticpatients.Int.J.Cardiol.2006;111:80-5.
44.TaskinenM.R.:LDL-cholesterol,HDL-cholesterolortriglycerides-whichistheculprit?DiabetesRes.Clin.Pract.2003;
61(supl.1):S19-26.
45.MillerM.:Ishypertriglyceridaemiaanindependentriskfactorforcoronaryheartdisease?Theepidemiologicaleviden-
ce.Eur.HeartJ.1998;19(supl.H):H18-22.
46.GottoA.M.Jr.:Triglycerideasariskfactorforcoronaryarterydisease.Am.J.Cardiol.1998;82:22Q-25Q.
47.HansenE.,HajriT.,AbumradN.N.:Isallfatthesame?Theroleoffatinthepathogenesisofthemetabolicsyndromeand
type2diabetesmellitus.Surgery2006;139:711-6.
48.Regitz-ZagrosekV.,LehmkuhlE.,WeickertM.O.:Genderdiferencesinthemetabolicsyndromeandtheirroleforcardio-
vasculardisease.Clin.Res.Cardiol.2006;95:136-47.
49.RomanskiS.A.,NelsonR.M.,JensenM.D.:Mealfattyaciduptakeinadiposetissue:genderefectsinnonobesehumans.
Am.J.Physiol.Endocrinol.Metab.2000;279:E455-62.
50.WellsJ.C.:Theevolutionofhumanfatnessandsusceptibilitytoobesity:anethologicalapproach.Biol.Rev.Camb.
Philos.Soc.2006;81:183-205.
51.GoldbergR.B.,CapuzziD.:Lipiddisordersintype1andtype2diabetes.Clin.Lab.Med.2001;21:147-72,vii.
52.SchwabK.O.,DoerferJ.,HeckerW.etal.(DPVInitiativeoftheGermanWorkingGroupforPediatricDiabetology):Spec-
trumandprevalenceofatherogenicriskfactorsin27,358children,adolescents,andyoungadultswithtype1diabetes:
cross-sectionaldatafromtheGermandiabetesdocumentationandqualitymanagementsystem(DPV).DiabetesCare
2006;29:218-25.
53.EkI.,ArnerP.,RydénM.etal.:Auniquedefectintheregulationofvisceralfatcelllipolysisinthepolycysticovarysyndro-
measanearlylinktoinsulinresistance.Diabetes2002;51:484-92.
54.SimhaV.,GargA.:Lipodystrophy:lessonsinlipidandenergymetabolism.Curr.Opin.Lipidol.2006;17:162-9.
55.DullooA.G.:Regulationoffatstorageviasuppressedthermogenesis:athriftyphenotypethatpredisposesindividuals
withcatch-upgrowthtoinsulinresistanceandobesity.Horm.Res.2006;65(supl.3):90-7.
56.HoltR.I.,ByrneC.D.:Intrauterinegrowth,thevascularsystem,andthemetabolicsyndrome.Semin.Vasc.Med.2002;2:
33-43.
57.HeilbronnL.,SmithS.R.,RavussinE.:Failureoffatcellproliferation,mitochondrialfunctionandfatoxidationresultsin
ectopicfatstorage,insulinresistanceandtypeIIdiabetesmellitus.Int.J.Obes.Relat.Metab.Disord.2004;28(supl.4):
S12-21.
58.WellenK.E.,HotamisligilG.S.:Obesity-inducedinflammatorychangesinadiposetissue.J.Clin.Invest.2003;112:1785-8.
59.DiehlA.M.,LiZ.P.,LinH.Z.,YangS.Q.:Cytokinesandthepathogenesisofnon-alcoholicsteatohepatitis.Gut.2005;54:
303-6.
60.KarpeF.,FieldingB.A.,IlicV.etal.:Impairedpostprandialadiposetissuebloodflowresponseisrelatedtoaspectsof
insulinsensitivity.Diabetes2002;51:2467-73.
61.JanssonP.A.,LarssonA.,LönnrothP.N.:Relationshipbetweenbloodpressure,metabolicvariablesandbloodflowin
obesesubjectswithorwithoutnon-insulin-dependentdiabetesmellitus.Eur.J.Clin.Invest.1998;28:813-8.
62.CapeauJ.,MagréJ.,LascolsO.,CaronM.etal.:Diseasesofadiposetissue:geneticandacquiredlipodystrophies.Bio-
chem.Soc.Trans.2005;33(Pt5):1073-7.
63.GabrielyI.,MaX.H.,YangX.M.,AtzmonG.etal.:Removalofvisceralfatpreventsinsulinresistanceandglucoseintole-
ranceofaging:anadipokine-mediatedprocess?Diabetes2002;51:2951-8.
64.BarzilaiN.,SheL.,LiuB.Q.etal.:Surgicalremovalofvisceralfatreverseshepaticinsulinresistance.Diabetes1999;48:94-8.
65.LihnA.S.,PedersenS.B.,RichelsenB.:Adiponectin:action,regulationandassociationtoinsulinsensitivity.Obes.Rev.
2005;6:13-21.
66.SartorB.M.,DickeyR.P.:Polycysticovariansyndromeandthemetabolicsyndrome.Am.J.Med.Sci.2005;330:336-42.
67.HolmC.:Molecularmechanismsregulatinghormone-sensitivelipaseandlipolysis.Biochem.Soc.Trans.2003;31(Pt
6):1120-4.
68.ShumB.O.,MackayC.R.,GorgunC.Z.etal.:Theadipocytefattyacid-bindingproteinaP2isrequiredinallergicairway
inflammation.J.Clin.Invest.2006;116(8):2183-2192.
69.WellenK.E.,HotamisligilG.S.:Inflammation,stress,anddiabetes.J.Clin.Invest.2005;115:1111-9.
70.SempleR.K.,ChatterjeeV.K.,O’RahillyS.:PPAR-γandhumanmetabolicdisease.J.Clin.Invest.2006;116:581-9.
71.CorellaD.,QiL.,TaiE.S.etal.:PerilipingenevariationdetermineshighersusceptibilitytoinsulinresistanceinAsian
womenwhenconsumingahigh-saturatedfat,low-carbohydratediet.DiabetesCare2006;29:1313-9.
72.ComuzzieA.G.,FunahashiT.,SonnenbergG.etal.:Thegeneticbasisofplasmavariationinadiponectin,aglobalendop-
henotypeforobesityandthemetabolicsyndrome.J.Clin.Endocrinol.Metab.2001;86:4321-5.
73.YangW.S.,ChuangL.M.:Humangeneticsofadiponectininthemetabolicsyndrome.J.Mol.Med.2006;84:112-21.
74.MenzaghiC.,TrischittaV.,DoriaA.:Geneticinfluencesofadiponectinoninsulinresistance,type2diabetes,andcardio-
vasculardisease.Diabetes2007;56:1198-209.
75.BerthierM.T.,HoudeA.,CôtéM.etal.:Impactofadiponectingenepolymorphismsonplasmalipoproteinandadipo-
nectinconcentrationsofviscerallyobesemen.J.Lipid.Res.2005;46:237-44.
